• Somatic and obstetrical aspects of magnesium deficiency (Clinical lecture)
To content

Somatic and obstetrical aspects of magnesium deficiency (Clinical lecture)

HEALTH OF WOMAN. 2016.8(114):10–17; doi 10.15574/HW.2016.114.10 
 

Somatic and obstetrical aspects of magnesium deficiency (Clinical lecture)


Shurpyak S. A.

Lviv national medical University named Danylo Galitsky


Homeostasis of magnesium in the body is a prerequisite for human health. As required macrocell for cells and tissues, magnesium is involved in many physiological processes, to ensure the normal functioning of the organism. At the same time a number of large-scale studies established a significant prevalence of magnesium deficiency, which is in the general population is 14.5%, and the suboptimal level observed in 33.7%. The resolution of the International Advisory Council for magnesium deficiency in obstetrics and gynecology noted urgency of the problem and the importance of correction of magnesium deficiency in pregnant and gynecological patients. The lecture covered various aspects of magnesium deficiency are considered violations of the pathophysiological mechanisms of magnesium homeostasis, Principles on the Use of magnesium products with preventive and curative purposes.


Key words: magnesium deficiency, clinical symptoms of hypomagnesemia, pregnancy.


REFERENCES

1. Budanov PV. 2010. Aktualnyie problemyi nevyinashivaniya beremennosti na fone defitsita magniya. Ginekologiya 5(1):28–32.

2. Budanov PV. 2012. Lechenie predmenstrualnogo sindroma: sovremennyie predstavleniya i perspektivyi. Trudnyiy patsient 10, 2–3:34–37.

3. Burchinskiy SG. Problema defitsita magniya v organizme: metodyi farmakologicheskoy korrektsii. – www.health–ua.com/articles/983.

4. Gorodetskiy VV, Talibov OB. 2007. Preparatyi magniya v meditsinskoy praktike. Malaya entsiklopediya magniya. M, ID Medpraktika-M.

5. Gromova OA. 2006. Vitaminyi i mikroelementyi pri beremennosti i u kormyaschih materey. Klinicheskaya farmakologiya. Obuchayuschie programmyi YuNESKO. Pod red. VM Sidelnikovoy. M:58.

6. Gromova OA, Serov VN, Torshin IYu. 2008. Magniy v akusherstve i ginekologii: istoriya primeneniya i sovremennyie vzglyadyi. Trudnyiy patsient 8:10–15.

7. Gromova OA. 2006. Magniy i piridoksin: Osnova znaniy. M, ProtoTip:230.

8. Dadak K. 2013. Defitsit magniya v akusherstve i ginekologii. Akusherstvo, ginekologiya i reproduktsiya 2:6–14.

9. Kosheleva NG, Arzhanova ON, Pluzhnikova TA. 2003. Nevyinashivanie beremennosti: etiopatogenez, diagnostika, klinika i lechenie. SPb:70.

10. Mezhevitinova EA, Prilepskaya VN, Nazarova NM. 2003. Rol magniya v razvitii predmenstrualnogo sindroma. Ginekologiya 2:23–33.

11. Mellina IM, Pavlovska TL, Vladymyrov OA, Tofan NI. 2002. Dosvid vykorystannia Mahne-V6 v akusherskii praktytsi. Pediatriia, akusherstvo ta hinekolohiia 2:119–123.

12. Mubarakshina OA. 2013. Osobennosti primeneniya preparatov magniya beremennyimi zhenschinami. Farmateka 18:2–5.

13. Mubarakshina OA. 2012. Sovremennyie podhodyi k primeneniyu preparatov magniya u beremennyih zhenschin. Akusherstvo i ginekologiya 5:109–112.

14. Nedogoda SV. 2009. Rol preparatov magniya v vedenii patsientov terapevticheskogo profilya. Lechaschiy Vrach 6:16–19.

15. Rol gipomagniemii v akusherskoy patologii. Primenenie preparatov magniya. Pod red. NG Koshelevoy. SPb. 2007.

16. Rol defitsita magniya v akusherstve i ginekologii (pozitsiya ekspertov). Kollektiv avtorov. Akusherstvo i ginekologiya. 2014:1.

17. Serov VN, Blinov DV, Zimovina UV, Dzhobava EM. 2014. Rezultatyi issledovaniya rasprostranennosti defitsita magniya u beremennyih. Akusherstvo i ginekologiya 6:33–39.

18. Serov VN, Kerimkulova NV, Torshin IYu, Gromova OA. 2012. Zarubezhnyiy i rossiyskiy opyit primeneniya magniya v akusherstve i ginekologii. Dokazatelnyie issledovaniya. Voprosyi ginekologii, akusherstva i perinatologii 11(4):62–72.

19. Spasov AA. 2000. Magniy v meditsinskoy praktike. Volgograd:272.

20. Tetruashvili NK, Sidelnikova VM. 2005. Vospolnenie defitsita magniya v kompleksnoy terapii patsientok s ugrozoy preryivaniya beremennosti. Trudnyiy patsient 3;2:20–23.

21. Torshin IYu, Gromova OA. 2008. Displaziya soedinitelnoy tkani, kletochnaya biologiya i molekulyarnyie mehanizmyi vozdeystviya magniya. RMZh. 16;4:230–238.

22. Torshin IYu, Gromova OA. 2009. Mehanizmyi antistressovogo i antidepressivnogo deystviya magniya i piridoksina. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova 109(11):107–111.

23. Torshin IYu, Rudakov KV, Tetruashvili NK i dr. 2010. Magniy, piridoksin i trombofiliya beremennyih: molekulyarnyie mehanizmyi i dokazatelnaya meditsina. Rossiyskiy vestnik akushera-ginekologa 4:67–71.

24. Fofanova IYu. 2013. Defitsit magniya i ego svyaz s akusherskoy patologiey. Meditsinskiy sovet 5:34–41.

25. Tsallagova EV. 2013. Magniy: perspektivyi zhenskogo i detskogo zdorovya. Farmateka 18:6–8.

26. Chushkov YuV. 2012. Sovremennyie vozmozhnosti korrektsii defitsita magniya v akusherstve. RMZh. 17:867–873.

27. Shilov AM, Avshalumov ASh, Sinitsina EN i dr. 2008. Metabolicheskiy sindrom i «defitsit magniya»: osobennosti techeniya i lecheniya. – www.vrach.ru.

28. Barbagallo M, Belvedere M, Dominguez LJ. 2009. Magnesium homeostasis and aging. Magnes. Res. 22;4:235–246.

29. Bussiere FI, Mazur A, Fauquert JL et al. 2002. High magnesium concentration in vitro decreases human leukocyte activation. Magnes Res. 15:43–48.

30. Classen HG. 2004. Magnesium orotate-experimental and clinical evidence. Rom. J. Intern. Med. 42(3):491–501.

31. Coudray C, Rambeau М, Feillecct-Coudray C et al. 2005. Study of magnesium bioavailability from ten organic and inorganic Mg salts in Mg-depleted rats using a stable isotope approach. Magnes. Res. 18(4):215–223.

32. Durlach J, Pages N, Bac P et al. 2002. Magnesium deficit and sudden infant death syndrome (SIDS): SIDS due to magnesium deficiency and SIDS due to various forms of magnesium depletion: possible importance of the chronopathological form. Magnes. Res. 15(3–4):269–278.

33. Fausto de Silva & Willams PJ. 2003. Biological chemisrty o felements. Cambrige:678.

34. Fox C, Ramsoomair D, Carter C. 2001. Magnesium: its proven and potential clinical significance. South Med J 94:1195–1201. https://doi.org/10.1097/00007611-200194120-00014https://doi.org/10.1097/00007611-200112000-00013; PMid:11811859

35. Guerrero-Romero F, Rodriguez-Moran M. 2006. Hypomagnesemia, oxidative stress, inflammation, and metabolic syndrome. Diabetes Metab. Res. Rev. 22(6):471–476.

36. Gunther T. 2010. The biochemical function of Mg 2+ in insulin secretion, insulin signal transduction and insulin resistance. Magnes. Res. 23(1):5–18.

37. Huang CL, Kuo E. 2007. Mechanism of Hypokalemia in Magnesium Deficiency. J Am Soc Nephrol 18(10):2649–2652. https://doi.org/10.1681/ASN.2007070792; PMid:17804670

38. Kenji Ueshima. 2005. Magnesium and ischemic heart disease: a review of epidemiological, experimental, and clinical evidences. Magnes. Res. 18(4):275–284.

39. Killilea DW, Maier JAM. 2008. A connection between magnesium deficiency and aging: new insights from cellular studies. Magnesium Research 21(2):77–82.

40. King DE. 2009. Inflammation and elevation of C-reactive protein: does magnesium play a key role? Magnes. Res. 22(2):57–59.

41. Konrad M, Weber S. 2003. Recent advances in molecular genetics of hereditary magnesium-losing disorders. J Am Soc Nephrol 14:249–260. https://doi.org/10.1097/01.ASN.0000049161.60740.CE; PMid:12506158

42. Mazur A, Maier JA, Rock E et al. 2007. Magnesium and the inflammatory response: potential physiopathological implications. Arch Biochem Biophys. 458(1):48–56.

43. Mittendorf R, Dammann O, Lee KS. 2006. Brain lesions in newborns exposed to high-dose magnesium sulfate during preterm labor. J. Perinatol. 26(1):57–63. https://doi.org/10.1038/sj.jp.7211419; PMid:16319938

44. Naderi ASA, Reilly R FJr. 2008. Hereditary etiologies of hypomagnesemia. Nature Clinical Practice Nephrology 4:80–89. https://doi.org/10.1038/ncpneph0680; PMid:18227801

45. National guidelines for hereditary disorders of connective tissue. Кардиоваскулярная терапия и профилактика. 2009. 8(6) Приложение 5:1–24.

46. Navarro JF, Mora-Fernаndez C. 2007. In: New perspectives in magnesium research: nutrition and health (Y. Nishizawa, H. Morii, J. Durlach, eds.) Springer-Verlag, London:303–315.

47. Okuno S, Inaba M. 2007. In: New perspectives in magnesium research: nutrition and health (Y. Nishizawa, H. Morii, J. Durlach, eds.) Springer-Verlag, London:316–329.

48. Rayssiguier Y, Mazur A. 2005. Magnesium and inflammation: lessons from animal models. Clin Calcium. 15(2):245–248.

49. Rodriguez-Moran M, Guerrero-Romero F. 2008. Serum magnesium and C-reactive protein levels. Arch Dis Child. 93(8):676–680. https://doi.org/10.1136/adc.2006.109371; PMid:17641003

50. Rosanoff A. 2005. Magnesium and hypertension. Clin. Calcium. 15:255–260.

51. Rouse DJ, Hirtz DG, Thom E, Varne MW et al. 2008. Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network. A randomized, controlled trial of agnesium sulfate for the prevention of cerebral palsy. N. Engl. J. Med. 359(9):895–905.

52. Rude RK. 1993. Magnesium metabolism and deficiency. Endocrinol Metab Clin North Am 22:377–395.

53. Ryan MF, Barbour H. 1998. Magnesium measurement in routine clinical practice. Ann Clin Biochem 35:449–459. https://doi.org/10.1177/000456329803500401

54. Saris NE, Mervaala E, Karppanen H, Khawaja JA, Lewenstam A. 2000. Magnesium. An update on physiological, clinical and analytical aspects. Clin Chim Acta 294:1–26. https://doi.org/10.1016/s0009-8981(99)00258-2

55. Schimatschek HF, Rempis R. 2001. Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. Magnes Res. 14:283–290.

56. Schlingmann KP, Konrad M, Seyberth HW. 2004. Genetics of hereditary disorders of magnesium homeostasis. Pediatr Nephrol 19:13–25. https://doi.org/10.1007/s00467-003-1293-z; PMid:14634861

57. Sheen E, Triadafilopoulos G. 2011. Adverse effects of long-term proton pump inhibitor therapy. Digestive diseases and sciences 56(4):931–950. https://doi.org/10.1007/s10620-010-1560-3; PMid:21365243

58. Song Y, Ridker PM, Manson JE et al. 2005. Magnesium intake, C-reactive protein, and the prevalence of metabolic syndrome in middle-aged and older U. S. women. Diabetes Care. 28:1438–1444. https://doi.org/10.2337/diacare.28.6.1438; PMid:15920065

59. Swaminathan R. 2003. Magnesium Metabolism and its Disorders. Clin Biochem Rev 24(2):47–66.

60. Tam M, Gomez S, Gonzalez-Gross M et al. 2003. Possible roles of magnesium on the immune system. Europ J Clin Nut. 57:1193–1197. https://doi.org/10.1038/sj.ejcn.1601689; PMid:14506478

61. Wu A. 2006. Tietz Clinical Guide to Laboratory Tests. 4th Ed. St. Louis, MO: Saunders Elsevier.